Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
BACKGROUND: Allergan Inc. recommends that its botulinum toxin type A (BTX-A; BOTOX) must be refrigerated and applied within 4 hours after its reconstitution to avoid losing its biologic effectiveness. OBJECTIVE: The objective was to compare clinical efficacy in treating external canthus dynamic line...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2007
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23840
- Acceso en línea:
- https://doi.org/10.1111/j.1524-4725.2007.33284.x
https://doi.org/10.1097/00042728-200711000-00005
https://repository.urosario.edu.co/handle/10336/23840
- Palabra clave:
- Botulinum toxin A
Botulinum toxin A
Adult
Article
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Eyelid
Facial nerve
Female
Follow up
Freezing
Human
Male
Nerve conduction
Priority journal
Randomized controlled trial
Dilution
Drug potency
Drug stability
Note
Adult
Botulinum Toxin Type A
Double-Blind Method
Drug Administration Schedule
Drug Storage
Face
Female
Humans
Male
Middle Aged
Neuromuscular Agents
Refrigeration
Skin Aging
- Rights
- License
- Bloqueado (Texto referencial)
Summary: | BACKGROUND: Allergan Inc. recommends that its botulinum toxin type A (BTX-A; BOTOX) must be refrigerated and applied within 4 hours after its reconstitution to avoid losing its biologic effectiveness. OBJECTIVE: The objective was to compare clinical efficacy in treating external canthus dynamic lines with reconstituted and refrigerated toxin (BTX-A) 1 week before its application versus fresh toxin (BTX-A). METHODS: This study was a double-blind, randomized, clinical trial. A total of 30 patients aged 30 to 60 years having a minimum of one and maximum of six external canthus dynamic lines were treated in one canthus with 15 U of BTX-A reconstituted and refrigerated at 4°C 1 week before being applied and in the other with 15 U of fresh BTX-A. Patients were followed-up on Day 10 and Weeks 6, 12, and 18; assessment included a neuroconduction study of the facial nerve and the investigators' photographic evaluation of the number of external canthus dynamic lines at maximum smile. RESULTS: Outcome measurement did not show statistically significant differences between both groups. CONCLUSION: BTX-A, reconstituted and refrigerated 1 week before its application, has similar clinical efficacy in treating external canthus dynamic lines as does fresh BTX-A. © 2007 by the American Society for Dermatologic Surgery, Inc. |
---|